IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01314118|
Recruitment Status : Active, not recruiting
First Posted : March 14, 2011
Results First Posted : January 7, 2015
Last Update Posted : May 30, 2018
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer Prostatic Neoplasm||Drug: abiraterone acetate in combination with prednisone||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||131 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease|
|Actual Study Start Date :||May 4, 2011|
|Actual Primary Completion Date :||December 24, 2013|
|Estimated Study Completion Date :||July 31, 2019|
abiraterone acetate in combination with prednisone Abiraterone acetate will be taken as 4 x 250 mg tablets by mouth (PO) once daily. Prednisone will be taken as 2 x 2.5 mg tablets PO once daily.
Drug: abiraterone acetate in combination with prednisone
Abiraterone acetate will be taken as 4 x 250 mg tablets by mouth (PO) once daily. Prednisone will be taken as 2 x 2.5 mg tablets PO once daily.
- Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) During the Core Study [ Time Frame: End of core study visit (Approximately at Month 6) ]Percentage of participants with greater than or equal to 50 percent decrease in PSA levels was assessed.
- Time to Radiographic Evidence of Disease Progression (TTRP) [ Time Frame: Maximum up to Month 30.5 ]Time to radiographic evidence of disease progression is defined as the time interval from the date of enrollment (Day 1) to the date of disease progression. A participant was considered as progressed by bone scan if: 1) The appearance of greater than or equal to (>=) 2 new lesions, and, following the first assessment, a confirmatory scan performed 6 or more weeks later that shows a minimum of 2 or more additional new lesions, 2) If >=2 new lesions are seen on scans following the first assessment, the confirmation is still required after 6 weeks; however, 2 addition lesions are not required to confirm progression, and 3) The date of progression is the date of the first scan that shows the changes.
- Time to Prostate-Specific Antigen (PSA) Progression [ Time Frame: Maximum up to Month 30.5 ]Time to PSA progression is defined as the time interval from the date of enrollment (Day 1) to the date of first evidence of PSA progression. A participant was considered to have a PSA progression if the PSA level had a 25 percent (%) or greater increase and an absolute increase of 2 nanogram (ng)/milliliter (mL) or more, which is confirmed by a second value obtained in 3 or more weeks.
- Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) Levels After 3 Cycles of Treatment [ Time Frame: End of Cycle 3 (Approximately Month 3) ]Percentage of participants with greater than or equal to 50 percent decrease in PSA levels was assessed. Decrease in PSA levels represented improvement.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01314118
Show 45 Study Locations
|Study Director:||Janssen Services, LLC. Clinical Trial||Janssen Biotech, Inc.|